Manifestasi dermatologi pada kejadian ikutan pasca vaksinasi COVID-19 booster Moderna pada mahasiswa tahap profesi Fakultas Kedokteran Universitas Mataram angkatan 2015-2017

Lisa Alverina; I Gusti Ayu Febi Risantari Risantari; I Wayan Hendrawan Hendrawan; Dedianto Hidajat Hidajat; I Gusti Agung Ayu Ratna Medikawati Medikawati; Dinie Ramdhani Kusuma Kusuma

doi:10.15562/ism.v14i1.1441

Manifestasi dermatologi pada kejadian ikutan pasca vaksinasi COVID-19 booster Moderna pada mahasiswa tahap profesi Fakultas Kedokteran Universitas Mataram angkatan 2015-2017

Lisa Alverina ,

I Gusti Ayu Febi Risantari ,

I Wayan Hendrawan ,

Dedianto Hidajat ,

I Gusti Agung Ayu Ratna Medikawati ,

Dinie Ramdhani Kusuma ,

pdf |
DOI: https://doi.org/10.15562/ism.v14i1.1441 |
Published: 2023-01-07

Abstract

Introduction: Indonesian Ministry of Health gave a third dose (booster) which was prioritized by the medical staff within 3 months since the second dose was given. The vaccine used for a booster is mRNA-1273 (Moderna) which had been approved by FDA (Food and Drug Administration) with modality mRNA and considerable efficacy. The adverse reaction to the skin which may present post-Moderna vaccination is a local reaction on the injection site on the first dose and increased on the second dose, delayed large local reaction on the first dose and decreased on the second dose. This study aims to determine the characteristics of dermatological lesions in the co-occurrence of post-COVID-19 booster Moderna vaccination in profession stage students of the Faculty of Medicine, Universitas Mataram, class of 2015-2017.

Method: The research design used was descriptive by taking data from respondents who received the Moderna booster who were students of the Faculty of Medicine, Universitas Mataram, class 2015-2017 and were willing to fill out a questionnaire.

Result: It was found that there were adverse reactions after vaccination as many as 90 respondents of 100 respondents with skin manifestations after Moderna booster vaccination, such as pain in the injection area (84%), edema (40%), erythema of the injection area (27%), itching (8%), urticaria (3%) and angioedema (1%). The onset of most symptoms occurred at 12-24 hours post-injection (33.3%) and 6-12 hours post-injection (23.3%).

Conclusion: There were skin manifestations in most of the respondents who received the Moderna vaccine booster (90%), with the most symptoms onset at 12-24 hours post-injection 33.3%.

Latar Belakang: Kementerian Kesehatan Republik Indonesia memberikan vaksinasi dosis ketiga (booster) yang diutamakan untuk tenaga kesehatan dengan jarak minimal 3 bulan setelah dosis kedua. Pemberian vaksin booster berupa vaksin mRNA-1273 (Moderna) yang diakui oleh FDA (Food and Drug Administration) dengan modalitas mRNA dan memiliki efikasi yang cukup besar. Efek samping pada kulit yang dapat muncul pasca vaksinasi Moderna adalah reaksi lokal pada tempat injeksi pada dosis pertama dan meningkat pada dosis kedua, delayed large local reaction pada dosis pertama dan menurun pada dosis kedua.

Tujuan: Penelitian ini bertujuan untuk mengetahui karakteristik lesi dermatologi pada kejadian ikutan pasca vaksinasi COVID-19 booster Moderna pada mahasiswa tahap profesi Fakultas Kedokteran Universitas Mataram angkatan 2015-2017.

Metode: Desain penelitian yang digunakan adalah deskriptif dengan cara mengambil data dari responden penerima booster Moderna yang merupakan mahasiswa tahap profesi Fakultas Kedokteran Universitas Mataram angkatan 2015-2017 dan bersedia mengisi kuesioner.

Hasil: Dari penelitian yang dilakukan didapatkan adanya kejadian ikutan pasca vaksinasi sebanyak 90 responden dari 100 responden dengan manifestasi kulit pasca vaksinasi booster Moderna berupa nyeri pada daerah injeksi (84%), edema (40%), eritema daerah injeksi (27%), gatal (8%), urtikaria (3%) dan angioedema (1%). Awitan timbulnya gejala terbanyak pada 12-24 jam pasca injeksi (33,3 %) dan 6-12 jam pasca injeksi (23,3%).

Simpulan: Terdapat manifestasi kulit pada sebagian besar responden yang menerima booster vaksin Moderna (90%) dengan awitan timbulnya gejala terbanyak pada 12 jam-24 jam pasca injeksi sebesar 33,3%.

References

Okamura S, Ebina H. Could live attenuated vaccines better control COVID-19?. Vaccine. 2021;39(39):5719-5726. doi:10.1016/j.vaccine.2021.08.018.
Cirrincione L, Plescia F, Ledda C, Rapisarda V, Martorana D, Moldovan RE, Theodoridou K, Cannizzaro E. COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at the Workplace. Sustainability. 2020; 12(9):3603. https://doi.org/10.3390/su12093603.
World Health Organization. COVID-19 advice for the public: Getting vaccinated [Internet]. WHO. 2021. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/COVID-19-vaccines/advice.
World Health Organization. World Health Organization Coronavirus (COVID-19) Dashboard [Internet]. WHO. 2021. Available from: https://COVID19.who.int/region/searo/country/id.
Nugraha RR, Miranda AV, Ahmadi A, Lucero-Prisno DE 3rd. Accelerating Indonesian COVID-19 vaccination rollout: a critical task amid the second wave. Trop Med Health. 2021;49(1):76. Published 2021 Sep 22. doi:10.1186/s41182-021-00367-3.
Ayatollahi A, Hosseini H, Firooz R, Firooz A. COVID-19 vaccines: What dermatologists should know?. Dermatol Ther. 2021;34(5):e15056. doi:10.1111/dth.15056.
Wei N, Fishman M, Wattenberg D, Gordon M, Lebwohl M. "COVID arm": A reaction to the Moderna vaccine. JAAD Case Rep. 2021;10:92-95. doi:10.1016/j.jdcr.2021.02.01.
McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55. doi:10.1016/j.jaad.2021.03.092.
Idayanti N, Sutiningsih D, Mochammad HM, and Abrori I. Adverse effects Associated with Third-Booster COVID-19 Vaccine (Heterologous Vaccines by Sinovac-Moderna) among Health Care Workers. IJELS. 2021;6(6). p250–252. DOI:10.22161/ijels.66.39.
Magro C, Crowson AN, Franks L, Schaffer PR, Whelan P, Nuovo G. The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin. Clin Dermatol. 2021;39(6):966-984. doi:10.1016/j.clindermatol.2021.07.011/.
Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide. Dermatol Clin. 2021;39(4):653-673. doi:10.1016/j.det.2021.05.016.
Watts MM, Maurer LE, Grammer LC, Saltoun CA, Stevens WW. Delayed angioedema after administration of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine. AAAI. 2022;128(2):215-216. doi:10.1016/j.anai.2021.10.021.
Pitlick MM, Joshi AY, Gonzalez-Estrada A, Chiarella SE. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination. Allergy Asthma Proc. 2022;43(1):40-43. doi:10.2500/aap.2022.43.210101.